Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orexo AB ( (SE:ORX) ) has issued an update.
Orexo AB’s US subsidiary has received an $8 million award from BARDA to support the development of OX390, an intranasal rescue medication for opioid overdoses. This funding is part of a larger potential $50.9 million package contingent on meeting specific milestones. OX390 aims to address the growing issue of adulterated opioid overdoses in the US using Orexo’s AmorphOX technology, with the company retaining commercial rights upon FDA approval.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners worldwide for other therapeutic areas. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
YTD Price Performance: 62.57%
Average Trading Volume: 34,085
Technical Sentiment Signal: Buy
Current Market Cap: SEK975.7M
For an in-depth examination of ORX stock, go to TipRanks’ Overview page.